PP-001 is a novel, non-steroidal immuno-modulatory small molecule. It is the active ingredient in Panoptes’ products PaniJect and PaniDrop. PP-001 is a highly specific nanomolar inhibitor of an essential enzyme of the de-novo pyrimidine pathway leading to inhibition of expression of IFN-γ and IL-17, two hallmark cytokines of Th1 and Th17 cells responsible for inflammatory diseases of the eye. Further, PP-001 reduces the host cell pyrimidine pool, which leads to inhibition of replication of many viruses especially adenovirus serotypes causing the highly contagious viral form of conjunctivitis.
PaniJect is injected into the eye to treat retinal diseases like uveitis, diabetic macular edema and retinal vein occlusion. Compelling efficacy by substantially improving visual acuity has been demonstrated in a clinical phase 1b/2a study in uveitis patients. Further, PaniJect demonstrated Excellent safety and tolerability in these patients.
PaniDrop is a novel and proprietary PP-001 eye drop formulation to treat diseases which manifest in the front of the eye like dry eye disease and viral or allergic conjunctivitis. It contains a protein-based nano-carrier and was developed by Panoptes to solve existing issues of currently marketed treatments. It improves delivery of the active component to the eye tissues and significantly improves tolerability (i.e. no stinging or burning sensation after dropping the eye). PaniDrop is currently investigated in a clinical study to demonstrate safety and tolerability. In animal models the high effectiveness to treat dry eye disease and viral conjunctivitis has already been demonstrated.